Literature DB >> 12525593

Alteplase: stability and bioactivity after dilution in normal saline solution.

Charles P Semba1, Suzanne Weck, Thomas Patapoff.   

Abstract

PURPOSE: To characterize the biochemical stability and bioactivity of reconstituted alteplase when diluted to a concentration of 0.01 mg/mL in normal saline solution and stored at ambient temperature for as long as 24 hours in commercial saline solution bags.
MATERIALS AND METHODS: Two commercially available formulations of lyophilized alteplase (2-mg and 50-mg vials, respectively) were reconstituted with sterile water to a final concentration of 1 mg/mL. For each vial configuration, 5 mg of alteplase (5 mL) was added to a commercial 500-mL bag of normal saline solution to achieve a 0.01-mg/mL targeted concentration. Solutions were assayed for optical clarity, pH, protein concentration, and in-vitro clot lysis activity. Assays of the solutions were performed at time points of 0 (control), 4, 8, and 24 hours at ambient room temperature and compared to controls.
RESULTS: On visual inspection, aliquots of the diluted protein solutions in clear glass vials remained clear/colorless after 24 hours. Bioactivity (clot lysis assay) over the course of 24 hours at ambient temperature remained essentially unchanged relative to control (2-mg vial: mean of 98.3%, range of 93.7%-103.3%; 50-mg vial: mean of 103.1%, range of 100.6%-108.3%). The mean protein recovery rates (relative to targeted concentration) over a 24-hour period were 43% (range, 39%-46%) and 42% (range, 40%-45%) for the 2-mg and 50-mg vial configurations, respectively.
CONCLUSIONS: Alteplase diluted in normal saline solution at a concentration of 0.01 mg/mL is biochemically stable and active at ambient temperature for as long as 24 hours as assessed by in vitro clot lysis assays. Alteplase appears to have a bimodal solubility profile in normal saline solution and further studies are required to determine the activity and solubility of alteplase concentrations lower than 0.01 mg/mL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525593     DOI: 10.1097/01.rvi.0000052297.26939.05

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.

Authors:  Sorina Morar-Mitrica; Manasi Puri; Alexandra Beumer Sassi; Joshua Fuller; Ping Hu; George Crotts; Douglas Nesta
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  How to perform and manage low-dose and slow/ultra-slow tissue type plasminogen activator infusion regimens in patients with prosthetic valve thrombosis.

Authors:  Ahmet Guner; Macit Kalcik; Mustafa Ozan Gursoy; Sabahattin Gunduz; Mehmet Ozkan
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 3.  Percutaneous Pulmonary Embolism Thrombectomy and Thrombolysis: Technical Tips and Tricks.

Authors:  Zlatko Devcic; William T Kuo
Journal:  Semin Intervent Radiol       Date:  2018-06-04       Impact factor: 1.513

4.  Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience.

Authors:  Xiong Khee Cheong; Andrea Yu-Lin Ban; Boon Hau Ng; Nik Nuratiqah Nik Abeed; Nik Azuan Nik Ismail; Nik Farhan Nik Fuad; Syed Zulkifli Syed Zakaria; Sheah Lin Ghan; Mohamed Faisal Abdul Hamid
Journal:  BMC Pulm Med       Date:  2022-05-17       Impact factor: 3.320

5.  Stability of alteplase for ultrasound-facilitated catheter-directed thrombolysis.

Authors:  John Fanikos; Kathleen Marquis; Leo Buckley; Lena K Tran; Kevin McLaughlin; Abby Jane Golash; Umberto Campia; Gregory Piazza; Jean M Connors; Samuel Z Goldhaber
Journal:  Blood Adv       Date:  2021-12-14

6.  Changes in clot lysis levels of reteplase and streptokinase following continuous wave ultrasound exposure, at ultrasound intensities following attenuation from the skull bone.

Authors:  Bjarne Madsen Härdig; Jonas Carlson; Anders Roijer
Journal:  BMC Cardiovasc Disord       Date:  2008-08-26       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.